Yale New Haven Health CEO Christopher O'Connor to step down after 14 years

Yale New Haven Health said Christopher O'Connor will step down as chief executive after 14 years leading Connecticut's largest health system, setting up a major leadership transition as the organization continues to recover financially and move ahead with capital projects.

Pamela Sutton-Wallace, the system's current president, was named acting CEO effective immediately. O'Connor will stay on as a special adviser during the transition while the Yale New Haven Health Board of Trustees begins a national search for a permanent successor.

Board chair Mary Farrell said O'Connor leaves the system in a strong position and praised his leadership during the pandemic. The announcement did not give an exact departure date, and it did not say whether Sutton-Wallace is being considered for the permanent role.

O'Connor's tenure

O'Connor's 14-year run coincided with a period of expansion for Yale New Haven Health. The reporting says he helped lead the acquisition of Hospital of Saint Raphael and later affiliations with Westerly Hospital, Lawrence + Memorial Hospital and Milford Hospital.

His tenure also included the COVID-19 pandemic, when major hospital systems faced staffing strain, higher costs and surging demand. The board's statement framed the transition as orderly rather than abrupt, with continuity built into the handoff.

The leadership change lands while the health system remains tied to a large capital project: the Adams Neurosciences Center at Yale New Haven Hospital's Saint Raphael campus, which is due to open in 2027. That project is part of the system's longer-term growth plan and remains a visible marker of O'Connor's era.

Financial context

The move also comes after a difficult financial stretch. Yale New Haven Health reported a $196.8 million operating loss for fiscal 2025, according to earlier reporting in February.

Later reporting said the system's operating loss narrowed to $7.6 million in the first half of fiscal 2026, suggesting some improvement even as cost pressure and Medicaid reimbursement concerns continue to weigh on the organization.

Earlier coverage in October 2025 said Yale New Haven Health had already been going through executive turnover amid restructuring and financial strain. Against that backdrop, O'Connor's departure looks less like an isolated personnel change and more like part of a broader reset.

What happens next

The immediate question is who will lead the system permanently. The board has not set a timeline for naming a successor, and the announcement left open how long Sutton-Wallace will serve as acting CEO.

The transition will matter beyond the executive suite. Yale New Haven Health is one of Connecticut's largest employers and a major regional hospital network, so the change reaches patients, staff, investors and local health care partners.

The board now has to balance continuity with change: keeping the organization steady while it works through financial recovery, labor and cost pressures, and the next stage of its capital program.

For now, the message from the system is that the transition is planned and controlled. But the search for a permanent CEO, and the pace of any further leadership changes, will determine how much continuity Yale New Haven Health can preserve.